HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ludwig, H. Articles by Meran, J. G. Search for Related Content PubMed PubMed Citation Articles by Ludwig, H. Articles by Meran, J. G. Related Collections Related Article

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

From the Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria (HL); Department of Internal Medicine I, Division of Oncology, University Hospital, Vienna, Austria (JD); Internal Department III, Krankenanstalt Rudolfstiftung, Vienna, Austria (HG); Department of Internal Medicine, LKH Feldkirch, Feldkirch, Austria (AL); Department of Internal Medicine, Krankenhaus der Barmherzigen Brueder, Vienna, Austria (JM)

Correspondence: Heinz Ludwig, Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1170 Vienna, Austria. E-mail: heinz.ludwig{at}wienkav.at

Paraprotein induced renal failure is a frequent complication of multiple myeloma and is associated with poor survival. Previously, reversal of renal function has been hampered by the lack of fast acting and highly effective myeloma therapy and most patients remained or became dependent on hemodialysis. Here we show reversal of acute paraprotein-induced renal failure by bortezomib-based therapy in 5 out of 8 patients. Improvement of renal function was preceded by a significant reduction in paraprotein concentration in all patients, with improvement in renal function.

Key words: acute paraprotein-induced renal failure, multiple myeloma, nephrotoxic light chains, bortezomib, hemodialysis.

Related Article

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

Roberto Sitia, Giovanni Palladini, Giampaolo Merlini
Haematologica 2007 92: 1302-1307. [Full Text] [PDF]

This article has been cited by other articles:

				R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF]